Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
News originally published by
GlobeNewswireSOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences:
Guggenheim Healthcare Innovation Conference
Presentation: Tuesday, November 10 at 11:30 a.m. EST
Boston, MA
LifeSci Growth and Innovation Summit
1x1 Meetings: Monday, November 16
London, U.K.
Jefferies Global Healthcare Conference London
Presentation: Tuesday, November 17 at 8:00 a.m. GMT
London, U.K.
Live webcasts of the presentations at the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference London will be available on the “Events & Presentations” section within the Investors page on the Lisata website. Replays of the webcasts will be available following each event.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company’s lead product candidate, MAR001, is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company. Following its acquisition of Marea, Lisata’s lead product candidate is MAR001, which is in Phase 2b clinical development for the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by very high triglyceride levels. The company is also advancing MAR002 for the treatment of acromegaly.
Contacts:
Lisata:
Investors and Media:
John Menditto
jmenditto@lisata.com
Marea:
Media:
1AB
Katie Engleman
katie@1abmedia.com
Investors:
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
